It is learned that the genital infection of herpes simplex virus type 2 (HSV-2) is one of the common diseases which have been linked to the increase in chances of contracting the HIV virus and its speedy acquisition. The disease can be prevented through the primary means in which the potential acquisition can be barred from happening. According to a study by Marrazzo et al. (2014) , there was a measure of Tenofovir (TFV) in the prevention of HSV-2 among women . This method is realized to be one of the primary prevention approaches and its study was important in establishing its effectiveness.
Tenofovir is a prevention method and should not be construed to be a vaccine. It is a drug informed approach of prevention which is administered to prevent the contraction of HSV-2 and to prevent the replication and spread of HIV virus from those infected (Marrazzo et al., 2014). It is given in a quantity of about 300mg on a daily basis. The measure of TFV on a quarterly basis is informed by the need to measure the use of the gel. The study was conducted among women in VOICE. There were a total of 2566 participants in this study. According to Marrazzo et al. (2014), these participants were evaluated and found to be at a higher risk of contracting the infection. 94% of the participants were found to be in the first quarter plasma while at the same time it was realized that there was a given amount of serology available.
Delegate your assignment to our experts and they will do the rest.
It was concluded from the study that the detection of plasma Tenofovir among the gel users could be associated with the trend of reduced cases of HSV-2 transmission and acquisition. This is possible after a reduced and controlled sexual behavior as well as HIV-1 acquisition (Marrazzo et al., 2014). The coitus related gel has been proven to be an effective and safer way of HIV prevention and other viral diseases such as HSV-2 (Karim et al., 2010). Therefore, this study is appropriate and can be used to fill the gap existing in the prevention of sexually transmitted diseases. Finally, this study raises inquisitiveness on the possibility of future research improving the actual identification of viral factors and hosts which are directly associated with early control across different clades. The early control of viral infections is seen as a progressive stride which can help in getting the HIV vaccine in the future.
References
Karim, Q. A., Karim, S. S. A., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., ... & Gengiah, T. N. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. science , 1193748.
Marrazzo, J., Rabe, L., Kelly, C., Livant, E., Chirenje, Z. M., Richardson, B., ... & VOICE Study Team. (2014). Association of tenofovir (TFV) detection with reduced risk of herpes simplex virus type-2 (HSV-2) acquisition in the VOICE (MTN 003) study. AIDS research and human retroviruses , 30 (S1), A31-A31.
